Sterling Capital Management LLC Grows Position in Edwards Lifesciences Corporation (EW)

Sterling Capital Management LLC increased its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 108.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,880 shares of the medical research company’s stock after acquiring an additional 12,449 shares during the quarter. Sterling Capital Management LLC’s holdings in Edwards Lifesciences Corporation were worth $2,824,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in shares of Edwards Lifesciences Corporation by 2.0% in the 2nd quarter. Vanguard Group Inc. now owns 20,748,569 shares of the medical research company’s stock valued at $2,453,311,000 after purchasing an additional 406,901 shares during the last quarter. BlackRock Inc. increased its holdings in Edwards Lifesciences Corporation by 0.8% in the 2nd quarter. BlackRock Inc. now owns 14,109,514 shares of the medical research company’s stock worth $1,668,309,000 after buying an additional 105,819 shares during the period. State Street Corp increased its holdings in Edwards Lifesciences Corporation by 1.7% in the 1st quarter. State Street Corp now owns 9,388,994 shares of the medical research company’s stock worth $883,219,000 after buying an additional 157,844 shares during the period. Bank of New York Mellon Corp increased its holdings in Edwards Lifesciences Corporation by 161.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock worth $627,207,000 after buying an additional 3,277,726 shares during the period. Finally, Winslow Capital Management LLC increased its holdings in Edwards Lifesciences Corporation by 0.8% in the 1st quarter. Winslow Capital Management LLC now owns 2,654,484 shares of the medical research company’s stock worth $249,707,000 after buying an additional 19,887 shares during the period. 81.90% of the stock is owned by institutional investors.

In related news, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction on Monday, July 31st. The stock was sold at an average price of $114.80, for a total value of $3,776,920.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Catherine M. Szyman sold 4,681 shares of Edwards Lifesciences Corporation stock in a transaction on Monday, July 31st. The stock was sold at an average price of $115.78, for a total value of $541,966.18. The disclosure for this sale can be found here. Insiders have sold a total of 182,201 shares of company stock worth $20,768,154 in the last ninety days. 2.13% of the stock is owned by company insiders.

WARNING: This piece was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://stocknewstimes.com/2017/10/16/sterling-capital-management-llc-grows-position-in-edwards-lifesciences-corporation-ew.html.

Edwards Lifesciences Corporation (EW) traded up 0.21% on Monday, hitting $108.48. The stock had a trading volume of 100,635 shares. The company has a market cap of $22.91 billion, a price-to-earnings ratio of 32.90 and a beta of 0.62. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.45. The company’s 50 day moving average price is $111.37 and its 200-day moving average price is $111.56.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.20. The business had revenue of $842.00 million for the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business’s revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the business posted $0.76 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

Several equities analysts recently weighed in on EW shares. SunTrust Banks, Inc. increased their price target on shares of Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a report on Monday, July 17th. Jefferies Group LLC reiterated a “buy” rating and issued a $115.00 price target on shares of Edwards Lifesciences Corporation in a report on Friday, June 30th. Canaccord Genuity reiterated a “buy” rating and issued a $150.00 price target on shares of Edwards Lifesciences Corporation in a report on Wednesday, June 28th. Stifel Nicolaus reaffirmed a “buy” rating and set a $130.00 price objective (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Finally, Bank of America Corporation raised their price objective on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, July 27th. Seven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $120.75.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply